Last reviewed · How we verify
100% Oxygen
At a glance
| Generic name | 100% Oxygen |
|---|---|
| Also known as | 100% O2, O2, Medical oxygen, FiO2 100% |
| Sponsor | Duke University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial). Investigator-initiated, International, Multicentre, Superiority, Randomized, Open-label, Clinical Trial. (PHASE4)
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission (PHASE3)
- Effects of Different Oxygen Concentrations on Pulmonary Complications in Patients Undergoing Radical Resection of Esophageal Cancer (PHASE4)
- High-flow Nasal Cannula Versus Conventional Oxygen During Awake Tracheal Intubation With Difficult Airways (NA)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- The Effect of Role Differences on Learning and Self-Assessment in Simulation-Based Life Support Training Among Dental Students (NA)
- Effects of Treatments on Atopic Dermatitis (PHASE2)
- Optimal Number of Hyperbaric Oxygen Treatments for Carbon Monoxide Poisoning (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 100% Oxygen CI brief — competitive landscape report
- 100% Oxygen updates RSS · CI watch RSS
- Duke University portfolio CI